Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlos Jaramillo

Showing results (71-80 of 91) with videos related to

Pageof 10
Sort By:
The Lancet. Infectious Diseases|August 15, 2024
Antibody persistence and safety of a live-attenuated chikungunya virus vaccine up to 2 years after single-dose administration in adults in the USA: a single-arm, multicentre, phase 3b studyRobert McMahon, Sebastian Toepfer, Natascha Sattler, et al.
Vaccine|March 21, 2026
Post-marketing safety evaluation of the live-attenuated chikungunya vaccine (IXCHIQ)Gerard Timmy Vondeling, Julio Croda, Tomas Jelinek, et al.
Science Advances|May 17, 2017
Miocene flooding events of western AmazoniaCarlos Jaramillo, Ingrid Romero, Carlos D'Apolito, et al.
Military Medicine|December 10, 2020
An Examination of Chronic Pain Indices and the Updated Posttraumatic Stress Disorder Checklist for Diagnostic and Statistical Manual of Mental-Disorders-Fifth EditionElizabeth Lehinger, David E Reed, Paul Nabity, et al.
Lancet (London, England)|June 15, 2023
Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trialMartina Schneider, Marivic Narciso-Abraham, Sandra Hadl, et al.
Nature Medicine|February 6, 2026
Live-attenuated chikungunya vaccine in children: a randomized phase 2 trialPetronela Weisová, Susanne Scheiblauer, Jacqueline Ecker, et al.
Cephalalgia : an International Journal of Headache|September 2, 2020
Reason to doubt the ICHD-3 7-day inclusion criterion for mild TBI-related posttraumatic headache: A nested cohort studyDonald D McGeary, Patricia A Resick, Donald B Penzien, et al.
Intensive Care Medicine|September 20, 2015
Acute respiratory distress syndrome in patients with and without diffuse alveolar damage: an autopsy studyJosé A Lorente, Pablo Cardinal-Fernández, Diego Muñoz, et al.
The Journal of Infection|July 5, 2023
Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trialChristian Taucher, Rajeka Lazarus, Hanna Dellago, et al.
Science (New York, N.Y.)|April 2, 2021
Extinction at the end-Cretaceous and the origin of modern Neotropical rainforestsMónica R Carvalho, Carlos Jaramillo, Felipe de la Parra, et al.
Pageof 10

Showing results (71-80 of 91) with videos related to

Sort By:
Pageof 10
The Lancet. Infectious Diseases|August 15, 2024
Antibody persistence and safety of a live-attenuated chikungunya virus vaccine up to 2 years after single-dose administration in adults in the USA: a single-arm, multicentre, phase 3b studyRobert McMahon, Sebastian Toepfer, Natascha Sattler, et al.
Vaccine|March 21, 2026
Post-marketing safety evaluation of the live-attenuated chikungunya vaccine (IXCHIQ)Gerard Timmy Vondeling, Julio Croda, Tomas Jelinek, et al.
Science Advances|May 17, 2017
Miocene flooding events of western AmazoniaCarlos Jaramillo, Ingrid Romero, Carlos D'Apolito, et al.
Military Medicine|December 10, 2020
An Examination of Chronic Pain Indices and the Updated Posttraumatic Stress Disorder Checklist for Diagnostic and Statistical Manual of Mental-Disorders-Fifth EditionElizabeth Lehinger, David E Reed, Paul Nabity, et al.
Lancet (London, England)|June 15, 2023
Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trialMartina Schneider, Marivic Narciso-Abraham, Sandra Hadl, et al.
Nature Medicine|February 6, 2026
Live-attenuated chikungunya vaccine in children: a randomized phase 2 trialPetronela Weisová, Susanne Scheiblauer, Jacqueline Ecker, et al.
Cephalalgia : an International Journal of Headache|September 2, 2020
Reason to doubt the ICHD-3 7-day inclusion criterion for mild TBI-related posttraumatic headache: A nested cohort studyDonald D McGeary, Patricia A Resick, Donald B Penzien, et al.
Intensive Care Medicine|September 20, 2015
Acute respiratory distress syndrome in patients with and without diffuse alveolar damage: an autopsy studyJosé A Lorente, Pablo Cardinal-Fernández, Diego Muñoz, et al.
The Journal of Infection|July 5, 2023
Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trialChristian Taucher, Rajeka Lazarus, Hanna Dellago, et al.
Science (New York, N.Y.)|April 2, 2021
Extinction at the end-Cretaceous and the origin of modern Neotropical rainforestsMónica R Carvalho, Carlos Jaramillo, Felipe de la Parra, et al.
Pageof 10